|Dr. Robert T. McNally Ph.D.||Pres, Chief Exec. Officer & Director||167.82k||N/A||69|
|Dr. Harriet Latham Robinson Ph.D.||Co-Founder, Chief Scientific Officer Emeritus & Director||N/A||N/A||79|
|Mr. Mark W. Reynolds CPA||CFO & Corp. Sec.||240.33k||N/A||55|
|Dr. Farshad Guirakhoo Ph.D.||Chief Scientific Officer||271.57k||N/A||64|
|Mr. Donald G. Hildebrand||Founder, Chairman Emeritus and Consultant||N/A||N/A||76|
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines against infectious diseases and cancer using its novel vaccine platform in the United States. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the HIV Vaccines Trial Network, Centers for Disease Control and Prevention, United States Army Research Institute of Infectious Disease, Emory University, University of Georgia Research Foundation, University of Pittsburgh, Georgia State University Research Foundation, Peking University, University of Texas Medical Branch, Burnet Institute, American Gene Technologies, Inc., Viamune, Inc., The Scripps Research Institute, and Institute of Human Virology. GeoVax Labs, Inc. was founded in 2001 and is headquartered in Smyrna, Georgia.
GeoVax Labs, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.